Boehringer Ingelheim signed a potential $1 billion multi-year collaboration with Envisagenics to validate tumor-specific targets using the Envisagenics RNA splicing platform. The pact centers on identifying alternative splicing-derived targets with the goal of enabling first-in-class precision therapies across solid tumors. The agreement includes upfront funding and milestone-linked payments that could exceed $1 billion in potential value, with an option for Boehringer to exclusively license selected targets after research completion. Envisagenics’ SpliceCore platform is expected to run through target validation across multiple modality frameworks, including ADCs, T cell engagers, and multispecific antibodies. For investors and operating teams, the deal is notable for non-dilutive economics and for underwriting early science in a target class that is still underexploited compared with more established discovery inputs like mutational hotspots.